Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial - Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A. Hidalgo, Elmira Mamedova, Marcelo H. Losso, Ploenchan Chetchotisakd, Carlos Brites, Jörg Sievers, Dannae Brown, Judy Hopking, Mark Underwood, Maria Claudia Nascimento, Yogesh Punekar - Dissemin

Language
Login

Published in

Elsevier, The Lancet Infectious Diseases

DOI: 10.1016/s1473-3099(19)30036-2

Links

Elsevier

Tools

Export citation

Search in Google Scholar

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Journal article published in 2019 by Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A. Hidalgo, Elmira Mamedova, Marcelo H. Losso, Ploenchan Chetchotisakd, Carlos Brites, Jörg Sievers, Dannae Brown, Judy Hopking, Mark Underwood, Maria Claudia Nascimento, Yogesh Punekar and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO